Dosage;
Gonorrhoea, deep I.M injection as a single dose equivalent to 2g of spectinomycin, although a dose of 4g may sometimes be required,divided between two injection sites.
Multiple-dose courses have been used for the treatment of disseminated infections. Children over 2 years; 40mg/kg.
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Gono | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 2g | 1 | Injection | per vial | KES 280.00 |
| Togamycin | Pfizer Global Pharmaceuticals | Laborex Kenya Eurapharma Ltd | 2g | 1 | Injection | per vial | KES 1,067.00 |
| Spectinomycin | |
|---|---|
| Mode Of Action | binds to 50s sub-unit of the bacterial ribosome and inhibits bacterial protein synthesis by preventing attachment of aminoacyl transfer RNA to its acceptor site on the ribosome. This prevents peptide bond formation by peptidyl transferase. |
| Drug Indication | Gonorrhoea caused by penicillin-resistant bacteria or in penicillin allergic patients. |
| Precautions | Nausea, dizziness, fever, chills, insomnia and urticaria have occasionally occurred with single doses of spectinomycin. Anaphylaxis has occurred rarely. Mild to moderate pain has been reported after I.M injections. Alterations in kidney and liver functions and a decrease in haemoglobin and haematocrit values have occasionally been seen with repeated doses. Although a reduction in urine output has been seen after single and multiple doses, spectinomycin has not been noted to produce functional changes indicative of nephrotoxicity. |
| Contra-Indications | Hypersensitivity to spectinomycin. |
| Side Effects | Urticaria, dizziness, nausea, chills, fever, decrease in haemoglobin. |
| Dosage | Gonorrhoea, deep I.M injection as a single dose equivalent to 2g of spectinomycin, although a dose of 4g may sometimes be required, divided between two injection sites. Multiple-dose courses have been used for the treatment of disseminated infections. Children over 2 years; 40mg/kg. |
| Pregnancy Category | Category B1 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals have not shown evidence of an increased occurrence of foetal damage. |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Macrolides |